|
|
|
|
||
Re: For Porscheman. Updated list..See added #14 below: Proven through NUMP data, this will be multiples of where it is today once bought out or approved. (Which ever comes first.) The List 1. QIDP and Fast Track Status. 2. Initiated P3 with a possible data look in June 3. NUMP Data that supports at least a 100% improvement over current FDA guidelines. 4. Peer reviewed data to be presented at the National Kidney Foundation in late April/early May. 5. The Federal Government through CMS recognizing a real and genuine need for Neutrolin. (Cost vs Benefit analysis that is off the charts.) 6. Analyst's with a 3X+, hugely conservative upside. 7. An SP and short position that does not take into account any of the above. 8. Forgot to add..."Stupid Cheap".. under $5.00 Long and strong. Hang tough all. Feel free to add to this list of positives.. 1.Advanced discussions with the FDA regarding the second Phase 3 trial using Neutrolin in oncology patients on Total Parental Nutrition (TPN)2.Granted six provisional patents covering additional applications using taurolidine in sutures, hydrogels and mesh products. 3. Instituted a Cost Reduction Program that is designed to significantly reduce the cost of taurolidine manufacturing by up to 65 percent plus . 4. Upgrade to $7.00 by FBR. 5. Upgrade to $6.50 -$7.50 by Rodman and Rensahaw. 6. Confirming work and the need by CMS BEDMINSTER, NJ / ACCESSWIRE / March 23, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that an abstract titled, "Clinical and Economic Burden of Bloodstream Infections Following Central Venous Catheter Placement in the Intensive Care Unit" has been selected for a poster presentation at the ISPOR 21st Annual International Meeting to be held May 21-25, 2016 in Washington, DC. 7. New CEO this quarter. (Maybe)8. CMS open to alternative reimbursement mechanisms vs bundling for anti infective solutions. 9. CMS to require reporting of bloodstream infections which could affect reimbursement or penalize institutions with higher rates of infection. 10. CorMedix Inc. to Ring New York Stock Exchange Opening Bell May 18, 201611.CorMedix Inc. Announces Publication of New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections at the ISPOR 21st Annual International Meeting12. CorMedix Inc. Presented Post-Market Clinical Utility Data from Neutrolin(R) Usage Monitoring Program at 53rd Joint Congress of the European Renal Association - European Dialysis and Transplant Association 14. Expanding product lines: Catheters (CVC, TPN, Oncology, ICU/CCU), Plastic Surgery, Wound Care, Pediatric Neuroblastoma. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
15626 | Re: For Porscheman. Updated list.. | biolurker1 | 3 | 6/29/2016 2:59:51 PM |